Richard A. Bernstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard A. Bernstein has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
Aaron Lord
For the STROKE AF Investigators
2 shared publicationsAaron Tansy
For the STROKE AF Investigators
2 shared publicationsAbraham Thomas
For the STROKE AF Investigators
2 shared publicationsAlan Donsky
For the STROKE AF Investigators
2 shared publicationsAlejandro Magadan
For the STROKE AF Investigators
2 shared publicationsAli Al Balushi
For the STROKE AF Investigators
2 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (9) , 2907-2908
Clinical Value of the New AHA Cancer-Related Ischemic Stroke Criteria
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57  (9) , 2907-2908
Clinical Value of the New AHA Cancer-Related Ischemic Stroke Criteria
- 1 April 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55  (4) , 919-920
Data Over Dogma in Treatment of Cervical Artery Dissections
- 1 April 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55  (4) , 919-920
Data Over Dogma in Treatment of Cervical Artery Dissections
- Open Access
- 1 December 2023
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 80  (12) , 1277
Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease
Importance: The STROKE AF study found that in patients with prior ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year when monitored with an insertable cardiac monitor (ICM). The occurrence over subsequent years is unknown.Objectives: To compare the rates of AF detection through 3 years of follow-up between an ICM vs site-specific usual care in patients with prior ischemic stroke attributed to LAD or SVD.Design, Setting, and Participants: This multicenter, randomized (1:1) clinical trial took place at 33 sites in the US with enrollment between April 2016 and July 2019 and 3-year follow-up through July 2022. Eligible patients were aged 60 years or older, or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index ischemic stroke attributed to LAD or SVD within 10 days prior to ICM insertion. Of the 496 patients enrolled, 492 were randomized and 4 were excluded.Interventions: ICM monitoring vs site-specific usual care.Main Outcomes and Measures: The prespecified long-term outcome of the trial was AF detection through study follow-up (up to 3 years). AF was defined as an episode lasting more than 30 seconds, adjudicated by an expert committee.Results: In total, 492 patients were randomized and included in the analyses (median [IQR] age, 66 [60-74] years; 307 men [62.4%] and 185 women [37.6%]), of whom 314 completed 3-year follow-up (63.8%). The incidence rate of AF at 3 years was 21.7% (46 patients) in the ICM group vs 2.4% (5 patients) in the control group (hazard ratio, 10.0; 95% CI, 4.0-25.2; P < .001).Conclusions and Relevance: Patients with ischemic stroke attributed to LAD or SVD face an increasing risk of AF over time and most of the AF occurrences are not reliably detected by standard medical monitoring methods. One year of negative monitoring should not reassure clinicians that patients who have experienced stroke will not develop AF over the next 2 years.Trial Registration: ClinicalTrials.gov Identifier: NCT02700945
- 1 December 2023
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 80  (12) , 1277
Open AccessAtrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease
Importance: The STROKE AF study found that in patients with prior ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year when monitored with an insertable cardiac monitor (ICM). The occurrence over subsequent years is unknown.Objectives: To compare the rates of AF detection through 3 years of follow-up between an ICM vs site-specific usual care in patients with prior ischemic stroke attributed to LAD or SVD.Design, Setting, and Participants: This multicenter, randomized (1:1) clinical trial took place at 33 sites in the US with enrollment between April 2016 and July 2019 and 3-year follow-up through July 2022. Eligible patients were aged 60 years or older, or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index ischemic stroke attributed to LAD or SVD within 10 days prior to ICM insertion. Of the 496 patients enrolled, 492 were randomized and 4 were excluded.Interventions: ICM monitoring vs site-specific usual care.Main Outcomes and Measures: The prespecified long-term outcome of the trial was AF detection through study follow-up (up to 3 years). AF was defined as an episode lasting more than 30 seconds, adjudicated by an expert committee.Results: In total, 492 patients were randomized and included in the analyses (median [IQR] age, 66 [60-74] years; 307 men [62.4%] and 185 women [37.6%]), of whom 314 completed 3-year follow-up (63.8%). The incidence rate of AF at 3 years was 21.7% (46 patients) in the ICM group vs 2.4% (5 patients) in the control group (hazard ratio, 10.0; 95% CI, 4.0-25.2; P < .001).Conclusions and Relevance: Patients with ischemic stroke attributed to LAD or SVD face an increasing risk of AF over time and most of the AF occurrences are not reliably detected by standard medical monitoring methods. One year of negative monitoring should not reassure clinicians that patients who have experienced stroke will not develop AF over the next 2 years.Trial Registration: ClinicalTrials.gov Identifier: NCT02700945
- Top Cited PapersOpen Access
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325  (21) , 2169-2177
Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease
Data from 2020 indicate that the annual incidence of new or recurrent stroke in the US was approximately 795 000, of which 23% were recurrent strokes.1 Most strokes were ischemic (87%),1 and 2014 data suggests a confirmed diagnosis of atrial fibrillation (AF) was the presumed cause in 12% of cases each year,2 although this may be an underestimate because it did not account for undiagnosed AF.3 The risk of stroke was highest among patients with AF who had a stroke or a high CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex category) score.4 The identification of AF in patients with stroke, whether it is the cause of the index stroke, unmasked by it, or coexistent, is therefore crucial for secondary stroke prevention with guideline-recommended oral anticoagulation (OAC) therapy, although the minimum burden of AF that requires anticoagulation is unknown.5
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 325  (21) , 2169-2177
Top Cited PapersOpen AccessEffect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease
Data from 2020 indicate that the annual incidence of new or recurrent stroke in the US was approximately 795 000, of which 23% were recurrent strokes.1 Most strokes were ischemic (87%),1 and 2014 data suggests a confirmed diagnosis of atrial fibrillation (AF) was the presumed cause in 12% of cases each year,2 although this may be an underestimate because it did not account for undiagnosed AF.3 The risk of stroke was highest among patients with AF who had a stroke or a high CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex category) score.4 The identification of AF in patients with stroke, whether it is the cause of the index stroke, unmasked by it, or coexistent, is therefore crucial for secondary stroke prevention with guideline-recommended oral anticoagulation (OAC) therapy, although the minimum burden of AF that requires anticoagulation is unknown.5